Table 1.
Characteristics of patients in SGLT2 inhibitor clinical trials.
| Clinical Trial | Year | Drug (Dose) |
N | Age (Years) |
Median Follow-Up Period (Years) |
CVD | DM | Mean eGFR (mL/min/1.73 m2) |
|---|---|---|---|---|---|---|---|---|
| EMPA-REG | 2015 | Empagliflozin (10 mg, 25 mg) |
7020 | 63.1 | 3.1 | 100% | 100% | 74.1 |
| CANVAS | 2017 | Canagliflozin (100 mg, 300 mg) |
10142 | 63.3 | 2.4 | 65.6% | 100% | 76.5 |
| DECLARE-TIMI 58 | 2019 | Dapagliflozin (10 mg) |
17160 | 63.9 | 4.2 | 40.6% | 100% | 85.2 |
| CREDENCE | 2019 | Canagliflozin (100 mg) |
4401 | 63.0 | 2.6 | 50.40% | 100% | 56.2 |
| DAPA-HF | 2019 | Dapagliflozin (10 mg) |
4401 | 66.3 | 1.5 | 100% | 41.8% | 65.8 |
| EMPEROR-Reduced | 2020 | Empagliflozin (10 mg) |
4401 | 66.8 | 1.3 | 100% | 49.8% | 62.0 |
| DAPA-CKD | 2020 | Dapagliflozin (10 mg) |
4401 | 61.9 | 2.4 | 37.4% | 67.5% | 43.1 |
N, number; CVD, cardiovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate.